Yeah, I’m honestly not sure why I try and post there sometimes. I guess it’s the activity level that I’m drawn to but you sure need to be diligent in reading through the intentions from both sides.

I’m in the camp though that thinks this probably doesn’t get through the phase 2 trials without a BO. I’m not sure big pharma wants the share price creeping up before they offer something. I am curious your thoughts about what happens to the other solid tumor targets? Breast, ovarian adjunct therapy would be an incredible advancement. If this is sold, I would hope the valuation includes the eventual impact on all these various cell lines